Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) study

Journal of Endocrinological Investigation

Volumn 31, Issue 8, 2008, Pages 731-738

  Giustina, A ^a,j   Mancini, T ^b   Boscani, P F ^c   de Menis, E ^d   degli Uberti, E ^e   Ghigo, E ^f   Martino, E ^g   Minuto, F ^h   Colao, A ⁱ  

^a UNIVERSITY OF BRESCIA   (Italy)

^b San Marino Hospital   (Italy)

^c IPSEN   (France)

^d General Hospital   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j Endocrine Service Montichiari Hospital   (Italy)

more..

Author keywords

Acromegaly; Awareness; Cardiomyopathy; Echocardiography; Hypertension; Questionnaire

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; SOMATOSTATIN;

ACROMEGALY; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; ITALY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PROGNOSIS; QUESTIONNAIRE; VALVULAR HEART DISEASE;

EID: 56249085601     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346423     Document Type: Article

References (32)

1. Melmed S, Casanueva FF, Cavagnini F, et al. Acromegaly Treatment Consensus Workshop Participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002, 87: 4054-8.
2. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005, 153: 737-40.
3. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355: 2558-73.
4. Giustina A, Casanueva FF, Cavagnini F, et al. The Pituitary Society and the European Neuroendocrine Association. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003, 26: 1242-7.
5. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730-4.
6. Swearingen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998, 83: 3419-26.
7. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102-52.
8. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
9. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2007, 92: 1743-7.
10. Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004, 89: 5308-13.
11. Maison P, Chanson P. Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk. Nat Clin Pract Endocrinol Metab 2006, 2: 650-1.
12. Manelli F, Desenzani P, Boni E, et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999, 2: 205-10.
13. Giustina A, Boni E, Romanelli G, Grassi V, Giustina G. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 1995, 75: 1042-7.
14. Jaffrain-Rea ML, Minniti G, Moroni C, et al. Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 2003, 148: 193-201.
15. Fatti LM, Scacchi M, Lavezzi E, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf) 2006, 65: 626-30.
16. Gola M, Bonadonna S, Doga M, Giustina A. Clinical review: Growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 2005, 90: 1864-70.
17. Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990, 113: 921-5.
18. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006, 29: 86-93.
19. Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001, 4: 239-49.
20. Bennedbaek FN, Perrild H, Hegedüs L. Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin Endocrinol (Oxf) 1999, 50: 357-63.
21. Bennedbaek FN, Hegedüs L. Management of the solitary thyroid nodule: results of a North American survey. Clin Endocrinol Metab 2000, 85: 2493-8.
22. Minniti G, Moroni C, Jaffrain-Rea ML, et al. Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring. Clin Endocrinol (Oxf) 1998, 48: 149-52.
23. Jaffrain-Rea ML, Moroni C, Baldelli R, et al Relationship between blood pressure and glucose tolerance in acromegaly. Clin Endocrinol (Oxf) 2001, 54: 189-95.
24. Pietrobelli DJ, Akopian M, Olivieri AO, et al. Altered circadian blood pressure profile in patients with active acromegaly. Relationship with left ventricular mass and hormonal values. J Hum Hypertens 2001, 15: 601-5.
25. Terzolo M, Matrella C, Boccuzzi A et al. Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features. J Endocrinol Invest 1999, 22: 48-54.
26. Słowińska-Srzednicka J, Zgliczyński S, Soszyński P, Zgliczyński W, Jeske W. High blood pressure and hyperinsulinaemia in acromegaly and in obesity. Clin Exp Hypertens A 1989, 11: 407-25.
27. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000, 85: 193-9.
28. Bondanelli M, Bonadonna S, Ambrosio MR, et al. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Metabolism 2005, 54: 1174-80.
29. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355: 1575-81.
30. Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J 1992, 13: 51-6.
31. Herrmann BL, Bruch C, Saller B et al. Occurrence of ventricular late potentials in patients with active acromegaly. Clin Endocrinol (Oxf) 2001, 55: 201-7.
32. Colao A, Beck-Peccoz P, Angeli A, et al. A new slow-release formulation of lanreotide (autogel) in patients with active acromegaly: preliminary results of a multicenter, open, clinical study. 6th European Congress of Endocrinology, Lyon 26-30 April 2003, PO 158.